

ixazomib capsule (NINLARO)

Diagnosis Considered for Coverage:

- Advanced Multiple Myeloma
- Systemic Light Chain Amyloidosis
- Lymphoplasmacytic Lymphoma
- Waldenström Macroglobulinemia

Coverage Criteria:

For advanced multiple myeloma:

- Dose does not exceed 4 mg per day on days #1, #8, and #15 per 28-day cycle, **and**
- **For 1st line therapy request:** Intolerance or contraindication to using bortezomib based therapies.

For systemic light chain amyloidosis:

- Being used for relapsed or refractory disease, **and**
- One of the following:
 - a. Being used in combination with dexamethasone, or
 - b. Being used in combination with dexamethasone and lenalidomide,
- Dose does not exceed 4 mg per day on days #1, #8, and #15 per 28-day cycle.

For Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma:

- Being used in combination with rituximab and dexamethasone, **and**
- Dose does not exceed 4 mg per day on days #1, #8, and #15 per 28-day cycle.

Coverage Duration: one year

Effective Date: 11/29/2023